AIA
PTLA

Alera Investment Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Alera Investment Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-13
Closed – – 1385
2018
Q4 		$0 Buy
+13
New +$267 ﹤0.01% 1191

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Alera Investment Advisors's PTLA Position: Q1 2019 in Review

Alera Investment Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2019, closing a stake of 13 shares.

Alera Investment Advisors first reported a position in PTLA in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 209 funds tracked by Wall St. Rank hold PTLA as of Q1 2019.

  • Alera Investment Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Alera Investment Advisors sold 13 Portola Pharmaceuticals, Inc. shares in Q1 2019.
  • Alera Investment Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q4 2018 and held it in 1 quarter.
  • Alera Investment Advisors's Portola Pharmaceuticals, Inc. position peaked at $0 in Q4 2018.
  • 209 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2019.

Based on Alera Investment Advisors's 13F filing for Q1 2019, filed 14 May 2019.